Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment

Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment

Chengqi Yu,1 Leilei Jiang,2 Dan Yang,2 Xin Dong,2 Rong Yu,2 Huiming Yu2 1School of Basic Medical Science, Capital Medical University, Beijing, 100069, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Onc...

Full description

Bibliographic Details
Main Authors: Yu C, Jiang L, Yang D, Dong X, Yu R, Yu H
Format: Article
Language:English
Published: Dove Medical Press 2022-10-01
Series:OncoTargets and Therapy
Subjects:
anlotinib
pd-1 blockade
local advanced non-small cell lung cancer
angiogenesis
immunotherapy.
Online Access:https://www.dovepress.com/anlotinib-hydrochloride-and-pd-1-blockade-as-a-salvage-second-line-tre-peer-reviewed-fulltext-article-OTT

Internet

https://www.dovepress.com/anlotinib-hydrochloride-and-pd-1-blockade-as-a-salvage-second-line-tre-peer-reviewed-fulltext-article-OTT

Similar Items